Home > Press > US Patent Grant Extends VivaGel(R) Coverage to 2024
 |
Abstract:
Starpharma Holdings Limited (ASX: SPL) today announced that it has received notification of the grant in the US of a key patent specifically relating to the use of SPL7013 to protect against sexually transmitted infections (STIs).
US Patent Grant Extends VivaGel(R) Coverage to 2024
Melbourne, Australia | Posted on September 22nd, 2009The granting of this patent means that any product presentation of SPL7013 (the active ingredient in VivaGel(R) ) is now protected in the US for an additional five years until 2024, with a possible further 12 month extension to 2025. Given the importance of genital herpes and other STIs in the US, this market is clearly a major commercial opportunity for VivaGel(R) products.
This composition of matter patent is the third patent for VivaGel(R) to be granted in the US, and adds to the already extensive patent coverage for the product in 26 countries covering all major markets.
VivaGel(R) is being developed as a condom coating in collaboration with SSL International plc (LSE: SSL) , the world's leading condom company. SSL markets the global brand Durex(R), and holds approximately 40% of the global branded condom market. Following a deal announced in 2008, SSL has exclusive marketing rights for the VivaGel(R) coated condom.
Starpharma is also developing VivaGel(R) as a vaginal microbicide to prevent the transmission of STIs, including HIV and genital herpes.
####
About Starpharma
Starpharma Holdings Limited (ASX: SPL) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. In September 2008 Starpharma signed a full licence agreement with SSL International plc (LSE: SSL) to develop a VivaGel(R) coated condom. Starpharma's receipts under the agreement are estimated to exceed A$100m comprising royalties on SSL sales, further milestone payments, and development support.
For more information, please click here
Contacts:
Media:
Buchan Consulting
Rebecca Wilson
Tel: +61 3 9866 4722
Mob: +61 417 382 391
Ellie Papathanasiou
Tel: +61 2 9237 2800
Starpharma:
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
Ben Rogers
Company Secretary
+61 3 8532 2702
Copyright © PrNewswire
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Products
Spectradyne Partners with Particle Technology Labs for Measurement Services December 6th, 2018
Mode-Changing MEMS Accelerometer from STMicroelectronics Combines High Measurement Resolution and Ultra-Low Power for Industrial Applications November 7th, 2018
Fat-Repellent Nanolayers Can Make Oven Cleaning Easier October 17th, 2018
Aculon, Inc. Enters into Strategic Partnership Agreement with Henkel Corporation to Supply Key Mobile Device Manufacturers with NanoProof® PCB Waterproof Technology October 17th, 2018
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Personal Care/Cosmetics
DGIST and New Life Group launched a research project on "Functional beauty and health products using the latest nanotechnology" May 12th, 2023
A Comprehensive Guide: The Future of Nanotechnology September 13th, 2018
Graphene finds new application as anti-static hair dye: New formula works as well as commercial permanent dyes without chemically altering hairs March 22nd, 2018
Programmable materials find strength in molecular repetition May 23rd, 2016
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||